Nimbus Therapeutics LLC has entered into a...

Maze Therapeutics has presented glycogen [starch] synthase, muscle (GYS1) inhibitors reported to be useful for the treatment of cancer and Pompe disease.

Gilead Sciences Inc. has patented glucagon-like peptide 1 (GLP-1) receptor agonists reported to be useful for the treatment of type 2 diabetes, obesity, prediabetes, atherosclerosis, metabolic syndrome, stroke, nonalcoholic steatohepatitis and renal disorders, among other disorders.

Bionanosim Ltd. has discovered cannabinoid CB1 receptor antagonists reported to be useful for the treatment of metabolic disorders.

Eli Lilly & Co. has synthesized macrocyclic peptides acting as amylin receptor agonists, glucose- and/or triglyceride-lowering agents reported to be useful for the treatment of type 2 diabetes, obesity, dyslipidemia and nonalcoholic steatohepatitis.

Cell death induced by hypoxia is quite a common problem during pancreatic islet transplantation and is caused by insufficient revascularization of the grafts. It has been reported that the loss of NLR family pyrin domain containing 3 (NLRP3) in pancreatic islet cells protects them from hypoxia-induced cell death, so it was hypothesized that blockade of NLRP3 would improve pancreatic islet transplantation.